Acceleron Pharma (XLRN) Tops Q1 EPS by 14c

Acceleron Pharma (NASDAQ: XLRN) reported Q1 EPS of ($0.30), $0.14 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $3.31 million versus the consensus estimate of $2.85 million.

For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Gemini Space Station, Inc. (GEMI) Misses Q2 EPS by 32c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c